Bharat Biotech’s Nasal Vaccine will soon be trialed at AIIMS, know everything about BBV154

All India Institute of Medical Science (AIIMS) will soon trial Bharat Biotech’s Nasal Vaccine BBV154. These trials will be of the second and third phases. Research is going on in all the countries of the world regarding the vaccine given through the nose of Corona. On the other hand, Bharat Biotech’s nasal vaccine in India was approved for Phase II clinical trials in August.

According to the news agency ANI, sources have informed that the trials of nasal vaccine at AIIMS will start in the next few weeks. An application has been made to the Ethics Committee of AIIMS for permission for the trial.

Both doses will be taken in 28 days

Dr Sanjay Rai will be the principal investigator of this vaccine trial of Bharat Biotech. After getting approval from the Ethics Committee, both the doses of this vaccine will be given on the volunteer in between four weeks.

This is the first vaccine of its kind

This is the first such BBV154 corona vaccine in itself, which will be trialed on humans in India. The first trial was done on volunteers aged between 18 and 60 years. It was successful. After the results of the second phase, there will be a third phase trial. A successful trial of Covaxin has also been done on children aged 2 to 18 years in AIIMS.

How does the nasal spray vaccine work?

Nasal spray vaccine is given through the nose rather than by injection. It produces immunity in the inner parts of the nose. It is also considered more effective because the root of most air-borne diseases, including corona, is mainly the nose, and immunity in its internal parts proves to be more effective in preventing such diseases.

Spread the love

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top